

January 25, 2008

To Whom It May Concern

KYORIN Co., Ltd.
5, Kanda Surugadai 2-chome,
Chiyoda-ku, Tokyo
Securities Code: 4569; TSE 1st Section

KIPRES[®] RECEIVED APPROVALS FOR ADDITIONAL INDICATION
TO RELIEVE SYMPTOMS OF ALLERGIC RHINITIS

KYORIN Co., Ltd. announced today that its wholly owned subsidiary, KYORIN Pharmaceutical Co., Ltd. (Headquarter: Tokyo, President: Ikuo Ogihara) received today (i) approval of "Kipres[®] Tablets 10mg" (INN: montelukast sodium), leukotriene receptor antagonist and currently being marketed for the treatment of bronchial asthma, for an additional indication to relieve symptoms of allergic rhinitis in adults and (ii) marketing approval of new formulation "Kipres[®] Tablets 5mg" only for relief of symptoms of allergic rhinitis in adults.

Montelukast sodium has been developed by Merck & Co., Inc., Whitehouse Station, N.J., U.S.A., and KYORIN Pharmaceutical has been contributing to the asthma treatment through marketing products containing that compound as "Kipres[®] Tablets 10mg" for adults and "Kipres[®] Chewable Tablets 5mg" for pediatric patients aged 6 years and older since August 2001, and as "Kipres[®] Oral Granules 4mg" for pediatric patients aged 1 year and older but under 6 years since October 2007.

It is known that leukotriene is a major mediator in the pathologic condition of allergic rhinitis as well as bronchial asthma, and Merck & Co., Inc. had developed the montelukast sodium as allergic rhinitis therapeutic drug since its mechanism of action could have potential to improve symptoms of not only bronchial asthma but also allergic rhinitis. Montelukast sodium is to date approved for relief of symptoms of seasonal allergic rhinitis in fifty countries and of perennial allergic rhinitis in thirteen countries, and has a wealth of usage experience overseas. Further, domestic clinical trials in Japan with montelukast sodium showed its beneficial effects on three major symptoms of allergic rhinitis; stuffy nose, runny nose and sneezing, by administering it once a day before bedtime.

The profile of "Kipres[®] Tablets 10mg" and "Kipres[®] Tablets 5mg" is as follows:

- i) Improve three major symptoms of allergic rhinitis (stuffy nose, runny nose and sneezing) by administering them once a day before bedtime.
- ii) Long-term study in the patients with perennial allergic rhinitis showed durability of response for twelve weeks without waning.
- iii) Have an onset of action from the first dosing day.

KYORIN Pharmaceutical has been pursuing Franchise Customers Strategy under which the company has been concentrating its marketing resources on the fields of respiratory, ear nose throat (ENT), and urology. The company will continue to make efforts to further contribute to asthma and allergic rhinitis treatments through aiming to immediately penetrate Kipres into the markets of respiratory and ENT.

###

Contacts:
Management Planning Department
KYORIN Co., Ltd.
TEL: 3-3293-3414

<Products Profile>

1. Brand Name	Kipres [®] Tablets 10mg	Kipres [®] Tablets 5mg
2. Nonproprietary Name	Montelukast Sodium	
3. Indications	Bronchial Asthma, <u>Allergic Rhinitis</u>	
4. Dosage and Administration	<p>< Bronchial Asthma > Recommended dosage for adults is usually 10mg as montelukast orally administered once daily before bedtime.</p> <p>< <u>Allergic Rhinitis</u> > Recommended dosage for adults is usually 5-10mg as montelukast orally administered once daily before bedtime.</p>	
5. NHI Price	JPY 287.10 per tablet	Not yet listed
6. Packaging	PTP 28, 100, 140, and 420 tablets	PTP 28, 100, and 140 tablets

* NHI price listing for Kipres Tablets 5mg will be expected in April 2008.

Reference

1. Brand Name	Kipres [®] Oral Granules 4mg	Kipres [®] Chewable 5mg
2. Indications	Bronchial Asthma	
3. Dosage and Administration	Recommended dosage for pediatric patients aged 1 year or older but under 6 years is usually 4mg (1 packet) as montelukast orally administered once daily before bedtime.	Recommended dosage for pediatric patients aged 6 years or older is usually 5mg as montelukast orally administered once daily before bedtime.
4. NHI Price	JPY 268.80 per packet	JPY 268.80 per tablet
5. Packaging	Aluminum Packet 28, 100, and 140 packets	PTP 28 and 100 tablets